Please use this identifier to cite or link to this item: https://doi.org/10.1124/jpet.106.103606
Title: A mechanistic study on reduced toxicity of irinotecan by coadministered thalidomide, a tumor necrosis factor-α inhibitor
Authors: Yang, X.-X.
Hu, Z.-P.
Xu, A.-L.
Duan, W.
Zhu, Y.-Z.
Huang, M.
Sheu, F.-S. 
Zhang, Q.
Bian, J.-S.
Chan, E. 
Li, X.
Wang, J.-C.
Zhou, S.-F. 
Issue Date: 2006
Citation: Yang, X.-X., Hu, Z.-P., Xu, A.-L., Duan, W., Zhu, Y.-Z., Huang, M., Sheu, F.-S., Zhang, Q., Bian, J.-S., Chan, E., Li, X., Wang, J.-C., Zhou, S.-F. (2006). A mechanistic study on reduced toxicity of irinotecan by coadministered thalidomide, a tumor necrosis factor-α inhibitor. Journal of Pharmacology and Experimental Therapeutics 319 (1) : 82-104. ScholarBank@NUS Repository. https://doi.org/10.1124/jpet.106.103606
Abstract: Dose-limiting diarrhea and myelosuppression compromise the success of irinotecan (7-ethyl-10-[4-[1-piperidino]-1-piperidino] carbonyloxycamptothecin) (CPT-11)-based chemotherapy. A recent pilot study indicates that thalidomide attenuates the toxicity of CPT-11 in cancer patients. This study aimed to investigate whether coadministered thalidomide modulated the toxicities of CPT-11 and the underlying mechanisms using several in vivo and in vitro models. Diarrhea, intestinal lesions, cytokine expression, and intestinal epithelial apoptosis were monitored. Coadministered thalidomide (100 mg/kg i.p. for 8 days) significantly attenuated body weight loss, myelosuppression, diarrhea, and intestinal histological lesions caused by CPT-11 (60 mg/kg i.v. for 4 days). This was accompanied by inhibition of tumor necrosis factor-α, interleukins 1 and 6 and interferon-γ, and intestinal epithelial apoptosis. Coadministered thalidomide also significantly increased the systemic exposure of CPT-11 but decreased that of SN-38 (7-ethyl-10-hydroxycampothecin). It significantly reduced the biliary excretion and cecal exposure of CPT-11, SN-38, and SN-38 glucuronide. Thalidomide hydrolytic products inhibited hydrolysis of CPT-11 in rat liver microsomes but not in primary rat hepatocytes. In addition, thalidomide and its major hydrolytic products, such as phthaloyl glutamic acid (PGA), increased the intracellular accumulation of CPT-11 and SN-38 in primary rat hepatocytes. They also significantly decreased the transport of CPT-11 and SN-38 in Caco-2 and parental MDCKII cells. Thalidomide and PGA also significantly inhibited P-glycoprotein (PgP/MDR1), multidrug resistance-associated protein (MRP1)- and MRP2-mediated CPT-11 and SN-38 transport in MDCKII cells. These results provide insights into the pharmacodynamic and pharmacokinetic mechanisms for the protective effects of thalidomide against CPT-11-induced intestinal toxicity. Copyright © 2006 by The American Society for Pharmacology and Experimental Therapeutics.
Source Title: Journal of Pharmacology and Experimental Therapeutics
URI: http://scholarbank.nus.edu.sg/handle/10635/99849
ISSN: 00223565
DOI: 10.1124/jpet.106.103606
Appears in Collections:Staff Publications

Show full item record
Files in This Item:
There are no files associated with this item.

SCOPUSTM   
Citations

23
checked on Jul 21, 2018

WEB OF SCIENCETM
Citations

21
checked on Jun 11, 2018

Page view(s)

53
checked on Jul 6, 2018

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.